我們已在上線！進一步了解

Firefly Neuroscience

AIFF

市值 US$1600萬

1.02 USD

-0.08

7.27%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

1.03

+0.01

0.98%

1天

-7.27%

5天

-13.56%

1個月

9.67%

3個月

-11.3%

6個月

-38.18%

今年迄今

14.53%

1年

-61.22%

5年

-98.86%

10年

-98.86%

關於： Firefly Neuroscience Inc is an artificial intelligence company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. The firm is developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The company has one reportable segment: the BNA platform. The Company derives revenue from North America.

員工： 17

科技軟體－應用程式

新聞

正面

中性

負面

市場情緒 3個月

正面 20%

中性 80%

負面 0%

Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care

Firefly Neuroscience Inc. (NASDAQ:AIFF), an artificial intelligence company advancing precision neuroscience, partnered with NeuroSigma, Inc., a bioelectronic medical device firm, to expand clinician awareness and access to the Monarch eTNS System across the U.S.

Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

– Partnership will introduce NeuroSigma's second-generation Monarch eTNS ® System to Firefly's nationwide network of Evoke™ clinicians –

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience's Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial's AI-Native Operating System for Brain Medicine

– This integration of Firefly's FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial's August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the country's largest brain medicine clinical network –

Firefly Neuroscience's Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial's AI-Native Operating System for Brain Medicine

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its U.S. Food and Drug Administration (“FDA”) 510(k)-cleared, AI-powered EEG/ERP platform, Evoke™.

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides

Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD

– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company advancing precision neuroscience, today announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (“PTSD”) using brain scans collected on its FDA-510(k)-cleared Evoke System. The biomarker discovery emanates partly from Firefly's previously announced public-private partnership with the U.S. Department of War (“DoW”) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from PTSD and/or Traumatic Brain Injury (“TBI”).

Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD

With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World's First Known 200,000+ Standardized EEG/ERP Depository

- Firefly's total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters -

With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World's First Known 200,000+ Standardized EEG/ERP Depository

Firefly Confirms Public-Private Partnership with the Department of War

Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members

Firefly Confirms Public-Private Partnership with the Department of War

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive 1

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

What's Going On With Firefly Neuroscience Stock On Friday?

Firefly Neuroscience Inc. (NASDAQ: AIFF) shares are up on Friday as the company continues to make strides in its development of brain scan technologies.

What's Going On With Firefly Neuroscience Stock On Friday?

查看新聞排名

價格圖表採用Lightweight Charts™實作